

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7724280

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NEOTOPE NEUROSCIENCE LIMITED	12/22/2021

RECEIVING PARTY DATA

Name:	NOVO NORDISK A/S
Street Address:	NOVO ALLE 1
City:	BAGSVAERD
State/Country:	DENMARK
Postal Code:	2880

PROPERTY NUMBERS Total: 22

Property Type	Number
Application Number:	62109004
Application Number:	62266555
Application Number:	15009667
Application Number:	15201429
Application Number:	16789319
Application Number:	62109002
Application Number:	62266556
Application Number:	15009662
Application Number:	15201423
Application Number:	16129618
Application Number:	16584634
Application Number:	17307968
Application Number:	15009666
Application Number:	15844430
Application Number:	16767994
Application Number:	62569436
Application Number:	62598965
Application Number:	16753307
Application Number:	62569438
Application Number:	62579817

PATENT

Property Type	Number
Application Number:	62647582
Application Number:	16753661

CORRESPONDENCE DATA

Fax Number: (650)838-2001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-838-2000

Email: tami.tucker@alston.com

Correspondent Name: TAMARA TUCKER

Address Line 1: ALSTON & BIRD LLP

Address Line 2: 101 SOUTH TRYON STREET, SUITE 4000

Address Line 4: CHARLOTTE, NORTH CAROLINA 28280-4000

ATTORNEY DOCKET NUMBER:	044182/554929
--------------------------------	---------------

NAME OF SUBMITTER:	TAMARA TUCKER
---------------------------	---------------

SIGNATURE:	/Tamara Tucker/
-------------------	-----------------

DATE SIGNED:	01/04/2023
---------------------	------------

Total Attachments: 27

source=NNLtoNovoAssign#page1.tif
source=NNLtoNovoAssign#page2.tif
source=NNLtoNovoAssign#page3.tif
source=NNLtoNovoAssign#page4.tif
source=NNLtoNovoAssign#page5.tif
source=NNLtoNovoAssign#page6.tif
source=NNLtoNovoAssign#page7.tif
source=NNLtoNovoAssign#page8.tif
source=NNLtoNovoAssign#page9.tif
source=NNLtoNovoAssign#page10.tif
source=NNLtoNovoAssign#page11.tif
source=NNLtoNovoAssign#page12.tif
source=NNLtoNovoAssign#page13.tif
source=NNLtoNovoAssign#page14.tif
source=NNLtoNovoAssign#page15.tif
source=NNLtoNovoAssign#page16.tif
source=NNLtoNovoAssign#page17.tif
source=NNLtoNovoAssign#page18.tif
source=NNLtoNovoAssign#page19.tif
source=NNLtoNovoAssign#page20.tif
source=NNLtoNovoAssign#page21.tif
source=NNLtoNovoAssign#page22.tif
source=NNLtoNovoAssign#page23.tif
source=NNLtoNovoAssign#page24.tif
source=NNLtoNovoAssign#page25.tif
source=NNLtoNovoAssign#page26.tif

DATED 22 DECEMBER 2021

NOVO NORDISK A/S

and

NEOTOPE NEUROSCIENCE LIMITED

DEED OF ASSIGNMENT OF INTELLECTUAL PROPERTY

MATHESON

70 Sir John Rogerson's Quay
Dublin 2
Ireland

TEL: + 353 1 232 2000
www.matheson.com
54509051.1

THIS DEED OF ASSIGNMENT is dated 22 December 2021 (this "Deed").

BETWEEN:

1. **NOVO NORDISK A/S**, a stock based corporation incorporated under the laws of Denmark, with company CVR registration number 24256790, having its registered address at Novo Allé 1, 2880 Bagsvaerd, Denmark ("**Novo Nordisk**") and
2. **NEOTOPE NEUROSCIENCE LIMITED**, a private limited company incorporated under the laws of Ireland, with offices at 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 T804 Ireland ("**NNL**"),

(together the "**Parties**" and each individually a "**Party**").

WHEREAS:

- A. NNL is the legal and beneficial owner of the NNL Intellectual Property.
- B. In accordance with the terms of the Asset Transfer Agreement, NNL agreed to assign to Novo Nordisk, as of the date hereof, its entire right, title and interest in and to the NNL Intellectual Property for the consideration set out in the Asset Transfer Agreement.
- C. Accordingly, Novo Nordisk has agreed to accept an assignment of all rights, title and interests in the NNL Intellectual Property, as and from the Effective Date, on the terms set out in this Deed.

WITNESSES AS FOLLOWS:

1 Definitions

- 1.1 In this Deed and any further agreements based thereon between the Parties, the following definitions shall apply unless the context requires otherwise:

"**Affiliate**" means a corporation or other entity that controls, is controlled by or is under common control with such corporation or entity. A person or entity shall be regarded as in control of another entity if it owns or controls more than fifty percent (50%) of the voting securities or other ownership interest of the other corporation or entity;

"**Assets**" has the meaning given to such term in the Asset Transfer Agreement;

"**Asset Transfer Agreement**" means the asset transfer agreement, dated in and around the date hereof, between (1) Novo Nordisk and (2) NNL, pursuant to which Novo Nordisk is to acquire all of the assets of NNL;

"**Effective Date**" means the date of this Deed;

"**Governmental Body**" means any national, federal, regional, state, local or foreign or other governmental authority or instrumentality, legislative body, court, administrative agency, regulatory body, commission or instrumentality, including any multinational authority having governmental or quasi-governmental powers, or any other self-regulated authority;

"Intellectual Property" means any and all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including:

- (i) all issued or granted patents (including all utility, utility model and design patents), pending patent applications (including all provisionals, nonprovisionals, national, regional and international applications, as well as original, continuation, continuation-in-part, divisional and continued prosecution applications, reissues, renewals, reversions, extensions and re-examination applications), statutory invention registrations and any term extension or other action by a Governmental Body which provides rights beyond the original expiration date of any of the foregoing, whether within or outside the United States ("**Patent Rights**");
- (i) trade marks, service marks, logos, trade names and trade dress, whether or not registered, and all pending applications for registration of the same, other than regulatory filings;
- (ii) copyrights, whether or not registered, and all pending applications for registration of the same;
- (iii) rights in domain names and URLs;
- (iv) trade secrets and other rights in Know-how (including inventions) and confidential or proprietary information;
- (v) rights in computer programs and databases, whether in object or source code form;
- (vi) registrations and applications for, and all goodwill associated with, any and all of the foregoing; and
- (vii) rights to sue and recover and retain damages, costs and attorneys' fees for past, present or future infringement, misappropriation or violation of any and all of the foregoing;

"Know-how" means any information, methods or techniques (whether in tangible or intangible form) necessary for or likely to assist in the manufacture or processing of products or in providing services in connection with or for the purposes of the Assets or to carry out any other activities in relation to the Assets and includes, without limitation, all instruction manuals, formulae, specifications, test results, process and product descriptions, market forecasts, and customer and supplier particulars;

"NNL Intellectual Property" means any Intellectual Property which is owned by NNL, including but not limited to that Intellectual Property which is listed in Schedule 1; and

"Person" Any individual, firm, partnership, company, corporation, government authority or other entity.

2 Assignment

- 2.1 In consideration for Novo Nordisk entering into the Asset Transfer Agreement and paying the consideration thereunder to NNL, NNL as legal and beneficial owner hereby assigns to Novo Nordisk its successors and assigns all its legal and beneficial right, title and interest in and to

the NNL Intellectual Property owned by NNL together with all rights of action, powers and benefits belonging to the same, including the right to sue for and obtain damages and other relief in respect of any infringement and / or any violation of any common law rights (whether past, present or future) in the NNL Intellectual Property and for Novo Nordisk, its successors and assigns to hold, use, exercise and enjoy the same unto Novo Nordisk absolutely for the whole period of such rights for the time being capable of being assigned by NNL together with any and all renewals, reversions and extensions throughout the world.

3 Further assurances

- 3.1 NNL will, upon written request and at the sole cost and expense of Novo Nordisk execute all such further assignments, transfers, deeds, documents or other assurances and to do all further acts and things as Novo Nordisk may require in order to enable Novo Nordisk to become registered as the proprietor or owner of the NNL Intellectual Property and otherwise to secure the benefit of the NNL Intellectual Property assigned under this Deed.

4 Miscellaneous

Force Majeure

- 4.1 Neither Party shall be liable for delay in the performance of any of its obligations hereunder if such delay results from causes beyond its reasonable control, including, without limitation, acts of God, fires, pandemics, strikes, acts of war, or intervention of any government authority, but any such delay or failure shall be remedied by such Party as soon as practicable.

Relationship of the Parties

- 4.2 Nothing contained in this Deed is intended or is to be construed to constitute Novo Nordisk and NNL as partners or joint ventures or employees of the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any third party.

Notices

- 4.3 All legal notices from one Party to the other will be in writing and will be given by addressing the same to the applicable address set forth below, or at such other address as either may specify in writing to the other. Notices shall be sent by overnight courier, certified mail with return receipt requested, or by other means of delivery requiring an acknowledged receipt. All notices shall be effective upon receipt.

To NNL:

Neotope Neuroscience Limited
77 Sir John Rogerson's Quay, Block C,
Grand Canal Docklands,
Dublin 2, D02 T804
Attention: Directors

To Novo Nordisk:

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Attention: Directors

Severability

- 4.4 If any provision in this Deed is deemed to be or becomes invalid, illegal or unenforceable, (i) such provision will be deemed amended to conform to applicable laws so as to be valid and enforceable or, if it cannot be so amended without materially altering the intention of the Parties, it will be deleted, and (ii) the validity, legality and enforceability of the remaining provisions of this Deed shall not be impaired or affected in any way.

Amendments

- 4.5 No amendment, modification or addition hereto shall be effective or binding on either Party unless set forth in writing and executed by a duly authorized representative of both Parties.

Waiver

- 4.6 To waiver of any right under this Deed shall be deemed effective unless contained in a writing signed by the Party charged with such waiver, and no waiver of any breach or failure to perform shall be deemed to be a waiver of any future breach or failure to perform or of any other right arising under this Deed.

Headings

- 4.7 The section headings contained in this Deed are included for convenience only and form no part of the agreement between the Parties.

Assignment, Etc.

- 4.8 Neither Party may assign its rights and obligations hereunder without the prior written consent of the other Party; provided, however, that either Party shall have the right to assign such rights and obligations hereunder to an Affiliate or to any Person with which such Party is merged or consolidated or which purchases all or substantially all of the assets of such Party.

Successors

- 4.9 This Deed will inure to the benefit of and be binding upon the successors and assigns of the Parties.

Counterparts

- 4.10 This Deed may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this Deed. This Deed may be executed by facsimile (including electronically by PDF). The Parties agree that facsimile copies of signatures have the same effect as original signatures.

Governing Law

- 4.11 This Deed shall be governed by and construed in accordance with the laws of Ireland.

SCHEDULE 1

NNL Intellectual Property

733 Family – Antibodies binding TTR epitope (the "733 Family")
 Owner: University Health Network (University of Toronto)

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
733-PRV	EXPIRED	United States	61/692,916	8/24/2012				
733-US	ISSUED	United States	13/974,761	8/23/2013	US 2014-0056904 A1	2/27/2014	9,534,048	1/3/2017
733-US2	ABANDONED	United States	15/373,657	12/9/2016	US 2017-0089929 A1	3/30/2017		
733-US3	PENDING	United States	16/198,965	11/23/2018	US 2019-0195896 A1	6/27/2019		

717 Family – Humanized 5A1 Antibodies (the "717 Family")
Owner: University Health Network (University of Toronto) and Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
717-AE	Pending	United Arab Emirates	P6000907/2017	2016-01-28				
717-AM	Registered/Granted	Armenia	201791710	2016-01-28			036014	2020-09-14
717-AR	Pending	Argentina	20160100238	2016-01-28				
717-AU	Allowed	Australia	2016210889	2016-01-28				
717-AZ	Registered/Granted	Azerbaijan	201791710	2016-01-28			036014	2020-09-14
717-BR	Published	Brazil	BR1120170163454	2016-01-28		7/23/2019		
717-BY	Registered/Granted	Belarus	201791710	2016-01-28			036014	2020-09-14
717-CA	Pending	Canada	2,974,993	2016-01-28				
717-CN	Published	China	201680015343.2	2016-01-28	CN 107406500 A	11/28/2017		
717-CO	Registered/Granted	Colombia	NC2017/0008482	2016-01-28		1/16/2018	37000	2020-01-27
717-CU	Allowed	Cuba	2017-0098	2016-01-28				
717-EA	Registered/Granted	Eurasian Patent	201791710	2016-01-28			036014	2020-09-14
717-EG	Pending	Egypt	PCT 2017/1224	2016-01-28				
717-EP	Allowed	European Patent Application	16702990.9	2016-01-28	3250593	12/6/2017		

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
717-EP-2	Published	European Patent Application	17746544.0	2017-06-30	3478716	5/8/2019		
717-HK	Pending	Hong Kong	16702990.9	2016-01-28				
717-HK-2	Pending	Hong Kong	17746544.0	2017-06-30				
717-ID	Pending	Indonesia	P00201705662	2016-01-28				
717-IN	Published	India	201727030355	2016-01-28	201727030355A	11/10/2017		
717-JP	Pending	Japan	2017-540250	2016-01-28				
717-JP-2	Pending	Japan	2018-568300	2017-06-30				
717-KG	Registered/Granted	Kyrgyzstan	201791710	2016-01-28			036014	2020-09-14
717-KR	Pending	Korea, Republic of	10-2017-7023750	2016-01-28				
717-KW	Pending	Kuwait	16/2016	2016-01-27				
717-KZ	Registered/Granted	Kazakhstan	201791710	2016-01-28			036014	2020-09-14
717-MX	Published	Mexico	MX/a/2017/09803	2016-01-28		9/14/2018		
717-MY	Pending	Malaysia	P/2017702752	2016-01-28				
717-PCT	Expired	PCT Application	PCT/IB2016/050416	2016-01-28	WO 2016/120811	8/4/2016		
717-PCT-2	Expired	PCT Application	PCT/IB2017/053991	2017-06-30	WO 2018/007924	1/11/2018		
717-PE	Published	Peru	1289-2017	2016-01-28	2018-0218	1/31/2018		

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
717-PK	Pending	Pakistan	59/2016	2016-01-27				
717-PRV	Expired	United States	62/109,004	2015-01-28				
717-PRV2	Expired	United States	62/266,555	2015-12-11				
717-RU	Registered/Granted	Russian Federation	201791710	2016-01-28			036014	2020-09-14
717-SA	Pending	Saudi Arabia	517381981	2016-01-28				
717-SG	Abandoned	Singapore	1120170612 6W	2016-01-28				
717-SG2	Published	Singapore	1020190669 6R	2016-01-28		8/27/2019		
717-TH	Pending	Thailand	1701004141	2016-01-28				
717-TJ	Registered/Granted	Tajikistan	201791710	2016-01-28			036014	2020-09-14
717-TM	Registered/Granted	Turkmenistan	201791710	2016-01-28			036014	2020-09-14
717-TW	Registered/Granted	Taiwan, Province of China	105102532	2016-01-27	201636371	10/16/2016	1711631	2020-12-01
717-TW2	Published	Taiwan, Province of China	109138086	2016-01-27	202110896	3/16/2021		
717-US	Abandoned	United States	15/009,667	2016-01-28	2016-0257737	9/8/2016		
717-US-2	Registered/Granted	United States	15/201,429	2016-07-02	2017-0015737	1/19/2017	10,633,433	2020-04-28
717-US-3	Allowed	United States	16/789,319	2020-02-12	2020-0277361	9/3/2020		

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
717-VE	Published	Venezuela, Bolivarian Republic of	2016-000046	2016-01-28		11/13/2017		
717-VN	Pending	Viet Nam	1-2017-03254	2016-01-28				
717-ZA	Registered/Granted	South Africa	2017/05664	2016-01-28			2017/05664	2018-09-26

723 Family – Humanized antibodies: PRX004 (humanized 14G8), 9D5 (the "723 Family")
Owner: University Health Network (University of Toronto) and Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
723-AE	Pending	United Emirates	P6000944/2017	2016-01-28				
723-AM	Registered/Granted	Armenia	201791712	2016-01-28			036080	2020-09-23
723-AR	Published	Argentina	20160100239	2016-01-28	AR103549A1	5/17/2017		
723-AU	Allowed	Australia	2016210888	2016-01-28				
723-AZ	Registered/Granted	Azerbaijan	201791712	2016-01-28			036080	2020-09-23
723-BR	Published	Brazil	BR1120170163306	2016-01-28		7/23/2019		
723-BY	Registered/Granted	Belarus	201791712	2016-01-28			036080	2020-09-23
723-CA	Pending	Canada	2,974,912	2016-01-28				

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
723-CL	Published	Chile	01924-2017	2016-01-28		4/27/2018		
723-CN	Registered/Granted	China	201680010882.7	2016-01-28	CN 107406499 A	11/28/2017	ZL201680010882.7	2021-10-22
723-CO	Registered/Granted	Colombia	NC2017/0008476	2016-01-28		1/16/2018	36461	2019-12-09
723-CU	Registered/Granted	Cuba	2017-0097	2016-01-28			24480	2020-02-25
723-EA	Registered/Granted	Eurasian Patent	201791712	2016-01-28			036080	2020-09-23
723-EG	Pending	Egypt	PCT 2017/1241	2016-01-28				
723-EP	Allowed	European Patent Application	16702812.5	2016-01-28	3250592	12/6/2017		
723-EP-2	Published	European Patent Application	17746542.4	2017-06-30	3478714	5/8/2019		
723-HK	Pending	Hong Kong	16702812.5	2016-01-28				
723-HK-2	Pending	Hong Kong	17746542.4	2017-06-30				
723-ID	Pending	Indonesia	P00201705573	2016-01-28				
723-IL	Registered/Granted	Israel	253633	2016-01-28		9/30/2017	253633	2021-10-01
723-IL2	Published	Israel	284022	2016-01-28		7/30/2021		
723-IN	Published	India	201727030354	2016-01-28	20172703035 4A	11/10/2017		
DIV of 723-JP	Pending	Japan	2020-133642	2016-01-28				
723-JP	Registered/Granted	Japan	2017-539650	2016-01-28			6748086	2020-08-11

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
723-JP-2	Pending	Japan	2018-568709	2017-06-30				
723-KG	Registered/Granted	Kyrgyzstan	201791712	2016-01-28			036080	2020-09-23
723-KR	Pending	Korea, Republic of	10-2017-7023749	2016-01-28				
723-KW	Pending	Kuwait	15/2016	2016-01-27				
723-KZ	Registered/Granted	Kazakhstan	201791712	2016-01-28			036080	2020-09-23
723-MX	Published	Mexico	MX/a/2017/009806	2016-01-28		9/14/2018		
723-MY	Pending	Malaysia	PI2017702751	2016-01-28				
723-NZ	Pending	New Zealand	733896	2016-01-28				
723-PCT	Expired	PCT Application	PCT/IB2016/050415	2016-01-28	WO 2016/1208106	8/4/2016		
723-PCT-2	Expired	PCT Application	PCT/IB2017/053984	2017-06-30	WO 2018/00792218	1/1/2018		
723-PE	Published	Peru	1287-2017	2016-01-28	2018-0217	1/31/2018		
723-PH	Allowed	Philippines	1-2017-501318	2016-01-28				
723-PK	Registered/Granted	Pakistan	60/2016	2016-01-27			143698	2021-09-09
723-PRV	Expired	United States	62/109,002	2015-01-28				
723-PRV2	Expired	United States	62/266,556	2015-12-11				
723-RU	Registered/Granted	Russian Federation	201791712	2016-01-28			036080	2020-09-23

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
723-SA	Allowed	Saudi Arabia	517382002	2016-01-28				
723-SG	Registered/Granted	Singapore	11201706124V	2016-01-28			11201706124V	2021-03-03
723-SG2 - 9D5 & 14G8	Published	Singapore	10202101763V	2016-01-28		4/29/2021		
723-TH	Published	Thailand	1701004140	2016-01-28	1701004140A	10/19/2020		
723-TJ	Registered/Granted	Tajikistan	201791712	2016-01-28			036080	2020-09-23
723-TM	Registered/Granted	Turkmenistan	201791712	2016-01-28			036080	2020-09-23
723-TW	Registered/Granted	Taiwan, Province of China	105102535	2016-01-27	201632554	9/16/2016	1718122	2021-02-11
723-TW2	Published	Taiwan, Province of China	110100085	2016-01-27	202124436	7/1/2021		
723-UA	Registered/Granted	Ukraine	a201708667	2016-01-28			122142	2020-09-25
723-US	Abandoned	United States	15/009,662	2016-01-28	2016-0251418	9/1/2016		
723-US-2	Registered/Granted	United States	15/201,423	2016-07-02	2017-0058023	3/2/2017	10,464,999	2019-11-05
723-US-3	Registered/Granted	United States	16/129,618	2018-09-12	2019-0071491	3/7/2019	10,669,330	2020-06-02
723-US-4	Registered/Granted	United States	16/584,634	2019-09-26	2020-0087386	3/19/2020	11,028,158	2021-06-08
723-US-5	Published	United States	17/307,968	2021-05-04	2021-0371507	12/2/2021		
723-VE	Published	Venezuela, Bolivarian Republic of	2016-000048	2016-01-28		11/13/2017		

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
723-VN	Pending	Viet Nam	1-2017-03253	2016-01-28				
723-ZA	Registered/Granted	South Africa	2017/05663	2016-01-28			2017/05663	2018-08-29

724 Family – Humanized 6C1 Antibodies (the "724 Family")
Owner: University Health Network (University of Toronto) and Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
724-AE	Pending	United Arab Emirates	P6000945/2017	2016-01-28				
724-AM	Registered/Granted	Armenia	201791711	2016-01-28			036048	2020-09-18
724-AR	Pending	Argentina	20160100240	2016-01-28				
724-AU	Allowed	Australia	2016210887	2016-01-28				
724-AZ	Registered/Granted	Azerbaijan	201791711	2016-01-28			036048	2020-09-18
724-BR	Published	Brazil	BR1120170163241	2016-01-28		7/23/2019		
724-BY	Registered/Granted	Belarus	201791711	2016-01-28			036048	2020-09-18
724-CA	Pending	Canada	2,974,911	2016-01-28				
724-CN	Allowed	China	201680015800.8	2016-01-28	CN107428822 A	12/1/2017		
724-CO	Abandoned	Colombia	NC2017/0008469	2016-01-28		1/16/2018		
724-CU	Registered/Granted	Cuba	2017-0096	2016-01-28			24532	2021-06-07

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
724-EA	Registered/Granted	Eurasian Patent	201791711	2016-01-28			036048	2020-09-18
724-EG	Pending	Egypt	PCT 2017/1240	2016-01-28				
724-EP	Registered/Granted	European Patent Application	16704940.2	2016-01-28	3250594	12/6/2017	3250594	2021-11-17
724-EP-2	Published	European Patent Application	17746543.2	2017-06-30	3478715	5/8/2019		
724-HK	Pending	Hong Kong	16704940.2	2016-01-28				2021-11-17
724-HK-2	Pending	Hong Kong	17746543.2	2017-06-30				2021-11-17
724-ID	Registered/Granted	Indonesia	P00201705659	2016-01-28			IDP000072944	2020-11-19
724-IN	Published	India	201727030352	2016-01-28	201727030352A	11/10/2017		
DIV of 724-JP	Pending	Japan	2021-072547	2016-01-28				
724-JP	Registered/Granted	Japan	2017-540249	2016-01-28			6875280	2021-04-26
724-JP-2	Pending	Japan	2018-568216	2017-06-30				
724-KG	Registered/Granted	Kyrgyzstan	201791711	2016-01-28			036048	2020-09-18
724-KR	Pending	Korea, Republic of	10-2017-7023748	2016-01-28				
724-KW	Pending	Kuwait	14/2016	2016-01-27				
724-KZ	Registered/Granted	Kazakhstan	201791711	2016-01-28			036048	2020-09-18
724-MX	Published	Mexico	MX/a/2017/009804	2016-01-28		9/14/2018		
724-MY	Pending	Malaysia	PI2017702749	2016-01-28				

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent or Registration Number	Issue Date
724-PCT	Expired	PCT Application	PCT/IB2016/050414	2016-01-28	WO 2016/120809	8/4/2016		
724-PCT-2	Expired	PCT Application	PCT/IB2017/053987	2017-06-30	WO 2018/007923	1/11/2018		
724-PE	Published	Peru	1286-2017	2016-01-28	2018-0200	1/31/2018		
724-PK	Registered/Granted	Pakistan	61/2016	2016-01-27			143699	2021-09-09
724-PRV	Expired	United States	62/109,001	2015-01-28				
724-PRV2	Expired	United States	62/266,557	2015-12-11				
724-RU	Registered/Granted	Russian Federation	201791711	2016-01-28			036048	2020-09-18
724-SA	Allowed	Saudi Arabia	517381991	2016-01-28				
724-SG	Registered/Granted	Singapore	11201706125Q	2016-01-28			11201706125Q	2021-10-20
724-TH	Published	Thailand	1701004139	2016-01-28	1701004139A	10/19/2020		
724-TJ	Registered/Granted	Tajikistan	201791711	2016-01-28			036048	2020-09-18
724-TM	Registered/Granted	Turkmenistan	201791711	2016-01-28			036048	2020-09-18
724-TW	Registered/Granted	Taiwan, Province of China	105102534	2016-01-27	201636372	10/16/2016	1718121	2021-02-11
724-TW2	Published	Taiwan, Province of China	110100084	2016-01-27	202118782	5/16/2021		
724-US	Abandoned	United States	15/009,666	2016-01-28	2016-0257736	9/8/2016		
724-US-2	Registered/Granted	United States	15/201,416	2016-07-02	2017-0121398	5/4/2017	9,879,080	2018-01-30
724-US-3	Abandoned	United States	15/844,430	2017-12-15				

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
724-US-4	Registered/Granted	United States	15/861,600	2018-01-03	2018-0201670	7/19/2018	10,494,426	2019-12-03
724-US-5	Registered/Granted	United States	16/669,375	2019-10-30	2020-0055929	2/20/2020	10,906,967	2021-02-02
724-US-6	Published	United States	17/127,719	2020-12-18	2021-0188956	6/24/2021		
724-VE	Published	Venezuela, Bolivarian Republic of	2016-000047	2016-01-28		11/13/2017		
724-VN	Pending	Viet Nam	1-2017-03255	2016-01-28				
724-ZA	Registered/Granted	South Africa	2017/05662	2016-01-28			2017/05662	2018-08-29

734 Family – PRX004 Formulation (the "734 Family")
Owner: Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
734-AE	Pending	United Arab Emirates	P6000761/2020	2018-11-28				
734-AU	Pending	Australia	2018375356	2018-11-28				
734-BR	Pending	Brazil	BR1120200104833	2018-11-28				
734-CA	Pending	Canada	3,083,356	2018-11-28				
734-CL	Published	Chile	01391-2020	2018-11-28		11/13/2020		
734-CN	Published	China	201880076019.0	2018-11-28	CN111433223 A	7/17/2020		

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
734-CO	Published	Colombia	NC/2020/0007683	2018-11-28		7/10/2020		
734-CU	Pending	Cuba	2020-0042	2018-11-28				
734-EA	Pending	Eurasian Patent	202091130	2018-11-28				
734-EG	Pending	Egypt	PCT 2020/749	2018-11-28				
734-EP	Published	European Patent Application	18882542.6	2018-11-28	3717512	10/7/2020		
734-HK	Pending	Hong Kong	18882542.6	2018-11-28				
734-ID	Pending	Indonesia	P00202003883	2018-11-28				
734-IL	Pending	Israel	274958	2018-11-28				
734-IN	Pending	India	202027027080	2018-11-28				
734-JO	Pending	Jordan	PCT/JO/2020/132	2018-11-28				
734-JP	Pending	Japan	2020-528890	2018-11-28				
734-KR	Pending	Korea, Republic of	10-2020-7015129	2018-11-28				
734-KW	Pending	Kuwait	000123/2020	2018-11-28				
734-MX	Published	Mexico	MX/a/2020/005433	2018-11-28		9/25/2020		
734-MY	Pending	Malaysia	PI2020002462	2018-11-28				

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
734-NZ	Pending	New Zealand	763869	2018-11-28				
734-PCT	Expired	PCT Application	PCT/US2018/062902	2018-11-28	WO 2019/108689	6/6/2019		
734-PE	Pending	Peru	000653-2020/DIN	2018-11-28				
734-PH	Pending	Philippines	1-2020-550694	2018-11-28				
734-PRV	Expired	United States	62/592,294	2017-11-29				
734-SA	Pending	Saudi Arabia	520412035	2018-11-28				
734-SG	Pending	Singapore	11202004187U	2018-11-28				
734-TH	Pending	Thailand	2001002882	2018-11-28				
734-UA	Pending	Ukraine	a202003269	2018-11-28				
734-US	Published	United States	16/767,994	2020-05-28	2020-0362023	11/19/2020		
734-VN	Pending	Viet Nam	1-2020-03373	2018-11-28				
734-ZA	Pending	South Africa	2020/03768	2018-11-28				

736 Family – 18C5 TTR antibody (the "736 Family")
Owner: Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
736-AE	Pending	United Arab Emirates	P6000506/2020	2018-10-05				
736-AR	Pending	Argentina	20180102878	2018-10-05				
736-AU	Pending	Australia	2018345806	2018-10-05				
736-BR	Pending	Brazil	BR1120200064343	2018-10-05				
736-CA	Pending	Canada	3,077,361	2018-10-05				
736-CN	Published	China	20188007178.1	2018-10-05	CN 111315213 A	6/19/2020		
736-CO	Published	Colombia	NC2020/0005583	2018-10-05		7/21/2020		
736-CU	Published	Cuba	2020-0021	2018-10-05		1/12/2021		
736-EA	Pending	Eurasian Patent	202090898	2018-10-05				
736-EG	Pending	Egypt	PCT 2020/562	2018-10-05				
736-EP	Published	European Patent Application	18863984.3	2018-10-05	3691447	8/12/2020		
736-HK	Published	Hong Kong	18863984.3	2018-10-05	40035184	5/7/2021		
736-ID	Published	Indonesia	P00202003245	2018-10-05	2021/PID/00029	1/4/2021		
736-IN	Pending	India	202027019147	2018-10-05				
736-JP	Pending	Japan	2020-518649	2018-10-05				
736-KR	Pending	Korea, Republic of	10-2020-7012722	2018-10-05				

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
736-KW	Pending	Kuwait	000124/2020	2018-10-05				
736-MX	Published	Mexico	MX/a/2020/003041	2018-10-05		11/24/2020		
736-MY	Pending	Malaysia	PI2020001697	2018-10-05				
736-PCT	Expired	PCT Application	PCT/US2018/054720	2018-10-05	WO 2019/071205	4/11/2019		
736-PE	Published	Peru	000481-2020/DIN	2018-10-05		3/17/2021		
736-PRV	Expired	United States	62/569,436	2017-10-06				
736-PRV2	Expired	United States	62/598,965	2017-12-14				
736-SA	Pending	Saudi Arabia	520411703	2018-10-05				
736-SG	Pending	Singapore	11202002489 Y	2018-10-05				
736-TH	Pending	Thailand	2001001962	2018-10-05				
736-US	Allowed	United States	16/753,307	2020-04-02	2020-0331992	10/22/2020		
736-VN	Pending	Viet Nam	1-2020-02512	2018-10-05				
736-ZA	Pending	South Africa	2020/02141	2018-10-05				

742 Family – Methods of detecting misfolded TTR and methods of treatment (the “742 Family”)
Owner: Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
742-AE	Pending	United Arab Emirates	P6000511/2020	2018-10-05				
742-AR	Pending	Argentina	20180102879	2018-10-05				
742-AU	Pending	Australia	2018345807	2018-10-05				
742-BR	Pending	Brazil	BR112020006791-1	2018-10-05				
742-CA	Pending	Canada	3,077,353	2018-10-05				
742-CN	Published	China	201880064631.6	2018-10-05	CN 111757730 A	10/9/2020		
742-CO	Published	Colombia	NC2020/0005587	2018-10-05		7/21/2020		
742-CU	Published	Cuba	2020-0022	2018-10-05		1/12/2021		
742-EA	Pending	Eurasian Patent	202090724	2018-10-05				
742-EG	Pending	Egypt	PCT 2020/561	2018-10-05				
742-EP	Published	European Patent Application	18864376.1	2018-10-05	3691626	8/12/2020		
742-HK	Pending	Hong Kong	18864376.1	2018-10-05				
742-ID	Pending	Indonesia	P00202003249	2018-10-05				
742-IN	Pending	India	202027019148	2018-10-05				
742-JP	Pending	Japan	2020-519805	2018-10-05				

Neotope Reference Number	Status	Country	Application Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
742-KR	Pending	Korea, Republic of	10-2020-7010132	2018-10-05				
742-KW	Pending	Kuwait	000128/2020	2018-10-05				
742-MX	Published	Mexico	MX/a/2020/003043	2018-10-05		11/24/2020		
742-MY	Pending	Malaysia	PI2020001764	2018-10-05				
742-PCT	Expired	PCT Application	PCT/US2018/054723	2018-10-05	WO 2019/071206	4/11/2019		
742-PE	Published	Peru	000647-2020/DIN	2018-10-05	2021-0042	1/8/2021		
742-PRV	Expired	United States	62/569,438	2017-10-06				
742-PRV2	Expired	United States	62/579,817	2017-10-31				
742-PRV3	Expired	United States	62/647,582	2018-03-23				
742-SA	Pending	Saudi Arabia	520411704	2018-10-05				
742-SG	Pending	Singapore	11202002490U	2018-10-05				
742-TH	Pending	Thailand	2001001963	2018-10-05				
742-US	Published	United States	16/753,661	2020-04-03	2020-0249244	8/6/2020		
742-VN	Published	Viet Nam	1-2020-02233	2018-10-05		11/25/2020		
742-ZA	Pending	South Africa	2020/02137	2018-10-05				

764 Family – Methods of treating TTR amyloidosis (monitor symptoms) (the “764 Family”)
Owner: Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
764-PCT	Published	PCT Application	PCT/US2021/018632	2021-02-18	WO 2021/168156	8/26/2021		
764-PRV	Expired	United States	62/979,373	2020-02-20				
764-PRV2	Expired	United States	63/022,342	2020-05-08				
764-TW	Published	Taiwan, Province of China	110105853	2021-02-19	202136298	10/12/2021		

774 Family – Methods of reducing and inhibiting misfolded TTR (the "774 Family")
Owner: Neotope Neuroscience Limited

Neotope Reference Number	Status	Country	Application or Serial Number	Filed Date	Publication Number	Publication Date	Patent Registration Number	Issue Date
774-PRV	PENDING	United States	63/106,653	10/28/2020				
774-PRV2	PENDING	United States	63/106,855	10/28/2020				
774-PRV3	PENDING	United States	63/122,720	12/8/2020				
774-PCT	PENDING PCT		PCT/US21/57150	10/28/2021				

EXECUTION VERSION

IN WITNESS WHEREOF, the Parties have executed and delivered this Deed of Assignment on the date last written below, effective as of the Effective Date.

Signed for and on behalf of

NEOTOPE NEUROSCIENCE LIMITED

and **DELIVERED** as a **DEED** by its lawfully
appointed attorney

David Scott

Attorney appointed under a
lawful power of attorney

Name: David Scott

Signed for and on behalf of
NOVO NORDISK A/S

KK

Authorised Signatory

Karsten Munk Knudsen
Executive Vice President

Name: Chief Financial Officer

Single

Marcus Schindler

Authorised Signatory

Marcus Schindler
Executive Vice President
Chief Science Officer

Name: Novo Nordisk A/S

[Signature Page to the NNL Intellectual Property Assignment Agreement]

EXECUTION VERSION

DATED 22 DECEMBER 2021

NOVO NORDISK A/S
AND
NEOTOPE NEUROSCIENCE LIMITED

DEED OF ASSIGNMENT OF
INTELLECTUAL PROPERTY

MATHESON
70 Sir John Rogerson's Quay
Dublin 2
Ireland

TEL: + 353 1 232 2000
www.matheson.com
54509051.1